查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1556598

转移性大肠直肠癌市场：趋势、预测和竞争分析（~2030 年）

Metastatic Colorectal Cancer Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计2024年至2030年全球转移性大肠直肠癌市场规模将以4.3%的复合年增长率成长。该市场的主要驱动因素是全球转移性大肠直肠癌盛行率的不断上升、癌症研究的不断进步以及单株抗体等标靶治疗的引入。全球转移性大肠直肠癌市场的未来充满希望，医院、癌症中心和门诊手术中心市场充满机会。

转移性大肠直肠癌分段预测

全球转移性大肠直肠癌市场的预测按治疗、药物类别、最终用途和地区提供。

转移性大肠直肠癌市场洞察

预计化疗在预测期内将出现最高成长。

在这个市场中，医院治疗预计将在预测期内实现最高成长。

预计北美地区在预测期内将出现最高的成长。

常问问题

Q1.市场成长预测是多少：

A1. 2024年至2030年，全球转移性大肠癌市场预计将以4.3%的复合年增长率成长。

Q2. 影响市场成长的关键驱动因素是：

A2. 该市场的主要驱动力是全球转移性结直肠癌盛行率的不断上升、癌症研究的不断进步以及单株抗体等标靶治疗的引入。

Q3.市场的主要细分市场是：

A3. 转移性大肠直肠癌市场前景广阔，医院、癌症中心和门诊手术中心市场充满机会。

Q4.市场的主要企业是：

A4. 转移性大肠直肠癌的主要企业如下：

  • Amgen
  • EMD Serono
  • Eli Lilly
  • Genentech
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche
  • Sanofi
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Oncology

Q5.未来最大的细分市场是什么？

A5.我们预计化疗将在预测期内达到最高成长。

Q6.未来五年预计哪些地区的市场成长最大？

A6. 预计北美地区在预测期内将出现最高成长。

Q7. 可以客製化报告吗？

A7. 是的，我们提供 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球转移性大肠直肠癌市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球转移性大肠直肠癌市场趋势（2018-2023）与预测（2024-2030）
  • 全球转移性大肠直肠癌市场：依治疗分类
    • 化疗
    • 标靶治疗
    • 免疫疗法
    • 单一疗法/联合治疗
    • 其他的
  • 全球转移性大肠直肠癌市场：依药物类别
    • 抗EGFR抑制剂
    • 抗VEGF治疗
    • 抗 HER2 治疗
    • 免疫查核点抑制剂
    • 其他的
  • 全球转移性大肠直肠癌市场：依最终用途分类
    • 医院
    • 癌症中心
    • 门诊手术中心
    • 其他的

第 4 章 2018-2030 年按地区分類的市场趋势与预测分析

  • 全球转移性大肠直肠癌市场：按地区
  • 北美转移性大肠直肠癌市场
  • 欧洲转移性大肠直肠癌市场
  • 亚太地区转移性大肠直肠癌市场
  • 其他地区转移性大肠直肠癌市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 透过治疗
    • 按药品类别
    • 按最终用途
    • 按地区
  • 全球转移性大肠直肠癌市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球转移性大肠直肠癌市场的产能扩张
    • 全球转移性大肠直肠癌市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Amgen
  • EMD Serono
  • Eli Lilly
  • Genentech
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche
  • Sanofi
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Oncology
简介目录

Metastatic Colorectal Cancer Trends and Forecast

The future of the global metastatic colorectal cancer market looks promising with opportunities in the hospital, cancer center, and ambulatory surgical center markets. The global metastatic colorectal cancer market is expected to grow with a CAGR of 4.3% from 2024 to 2030. The major drivers for this market are growing incidence of metastatic colorectal cancer globally, rising advancements in cancer research, and introduction of targeted therapies such as monoclonal antibodies.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Metastatic Colorectal Cancer by Segment

The study includes a forecast for the global metastatic colorectal cancer by treatment, drug class, end use, and region.

Metastatic Colorectal Cancer Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Chemotherapy
  • Targeted Therapies
  • Immunotherapies
  • Monotherapy & Combination Therapy
  • Others

Metastatic Colorectal Cancer Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Anti-EGFR Inhibitors
  • Anti-VEGF Therapies
  • Anti-HER2 Therapies
  • Immune Checkpoint Inhibitors
  • Others

Metastatic Colorectal Cancer Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Cancer Centers
  • Ambulatory Surgical Centers
  • Others

Metastatic Colorectal Cancer Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Metastatic Colorectal Cancer Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies metastatic colorectal cancer companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the metastatic colorectal cancer companies profiled in this report include-

  • Amgen
  • EMD Serono
  • Eli Lilly
  • Genentech
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche
  • Sanofi
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Oncology

Metastatic Colorectal Cancer Market Insights

Lucintel forecasts that chemotherapy is expected to witness the highest growth over the forecast period.

Within this market, hospital is expected to witness the highest growth over the forecast period.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Metastatic Colorectal Cancer Market

Market Size Estimates: Metastatic colorectal cancer market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Metastatic colorectal cancer market size by treatment, drug class, end use, and region in terms of value ($B).

Regional Analysis: Metastatic colorectal cancer market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatments, drug classes, end uses, and regions for the metastatic colorectal cancer market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the metastatic colorectal cancer market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for metastatic colorectal cancer market?

Answer: The global metastatic colorectal cancer market is expected to grow with a CAGR of 4.3% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the metastatic colorectal cancer market?

Answer: The major drivers for this market are growing incidence of metastatic colorectal cancer globally, rising advancements in cancer research, and introduction of targeted therapies such as monoclonal antibodies.

Q3. What are the major segments for metastatic colorectal cancer market?

Answer: The future of the metastatic colorectal cancer market looks promising with opportunities in the hospital, cancer center, and ambulatory surgical center markets.

Q4. Who are the key metastatic colorectal cancer market companies?

Answer: Some of the key metastatic colorectal cancer companies are as follows:

  • Amgen
  • EMD Serono
  • Eli Lilly
  • Genentech
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche
  • Sanofi
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Oncology

Q5. Which metastatic colorectal cancer market segment will be the largest in future?

Answer: Lucintel forecasts that chemotherapy is expected to witness the highest growth over the forecast period.

Q6. In metastatic colorectal cancer market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the metastatic colorectal cancer market by treatment (chemotherapy, targeted therapies, immunotherapies, monotherapy & combination therapy, and others), drug class (anti-EGFR inhibitors, anti-VEGF therapies, anti-HER2 therapies, immune checkpoint inhibitors, and others), end use (hospitals, cancer centers, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Metastatic Colorectal Cancer Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Metastatic Colorectal Cancer Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Metastatic Colorectal Cancer Market by Treatment
    • 3.3.1: Chemotherapy
    • 3.3.2: Targeted Therapies
    • 3.3.3: Immunotherapies
    • 3.3.4: Monotherapy & Combination Therapy
    • 3.3.5: Others
  • 3.4: Global Metastatic Colorectal Cancer Market by Drug Class
    • 3.4.1: Anti-EGFR Inhibitors
    • 3.4.2: Anti-VEGF Therapies
    • 3.4.3: Anti-HER2 Therapies
    • 3.4.4: Immune Checkpoint Inhibitors
    • 3.4.5: Others
  • 3.5: Global Metastatic Colorectal Cancer Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Cancer Centers
    • 3.5.3: Ambulatory Surgical Centers
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Metastatic Colorectal Cancer Market by Region
  • 4.2: North American Metastatic Colorectal Cancer Market
    • 4.2.1: North American Metastatic Colorectal Cancer Market by Treatment: Chemotherapy, Targeted Therapies, Immunotherapies, Monotherapy & Combination Therapy, and Others
    • 4.2.2: North American Metastatic Colorectal Cancer Market by End Use: Hospitals, Cancer Centers, Ambulatory Surgical Centers, and Others
  • 4.3: European Metastatic Colorectal Cancer Market
    • 4.3.1: European Metastatic Colorectal Cancer Market by Treatment: Chemotherapy, Targeted Therapies, Immunotherapies, Monotherapy & Combination Therapy, and Others
    • 4.3.2: European Metastatic Colorectal Cancer Market by End Use: Hospitals, Cancer Centers, Ambulatory Surgical Centers, and Others
  • 4.4: APAC Metastatic Colorectal Cancer Market
    • 4.4.1: APAC Metastatic Colorectal Cancer Market by Treatment: Chemotherapy, Targeted Therapies, Immunotherapies, Monotherapy & Combination Therapy, and Others
    • 4.4.2: APAC Metastatic Colorectal Cancer Market by End Use: Hospitals, Cancer Centers, Ambulatory Surgical Centers, and Others
  • 4.5: ROW Metastatic Colorectal Cancer Market
    • 4.5.1: ROW Metastatic Colorectal Cancer Market by Treatment: Chemotherapy, Targeted Therapies, Immunotherapies, Monotherapy & Combination Therapy, and Others
    • 4.5.2: ROW Metastatic Colorectal Cancer Market by End Use: Hospitals, Cancer Centers, Ambulatory Surgical Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Metastatic Colorectal Cancer Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Metastatic Colorectal Cancer Market by Drug Class
    • 6.1.3: Growth Opportunities for the Global Metastatic Colorectal Cancer Market by End Use
    • 6.1.4: Growth Opportunities for the Global Metastatic Colorectal Cancer Market by Region
  • 6.2: Emerging Trends in the Global Metastatic Colorectal Cancer Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Metastatic Colorectal Cancer Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Metastatic Colorectal Cancer Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Amgen
  • 7.2: EMD Serono
  • 7.3: Eli Lilly
  • 7.4: Genentech
  • 7.5: Novartis
  • 7.6: Pfizer
  • 7.7: F. Hoffmann-La Roche
  • 7.8: Sanofi
  • 7.9: Suzhou Zelgen Biopharmaceuticals
  • 7.10: Taiho Oncology